Aperio Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.9% during the 1st quarter, Holdings Channel reports. The firm owned 23,797 shares of the biopharmaceutical company’s stock after purchasing an additional 2,719 shares during the period. Aperio Group LLC’s holdings in Alnylam Pharmaceuticals were worth $2,834,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. grew its position in Alnylam Pharmaceuticals by 16.4% during the 4th quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock worth $903,969,000 after purchasing an additional 1,003,366 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in Alnylam Pharmaceuticals by 2.2% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,394,213 shares of the biopharmaceutical company’s stock worth $177,135,000 after purchasing an additional 29,816 shares during the last quarter. Geode Capital Management LLC grew its position in Alnylam Pharmaceuticals by 13.4% during the 4th quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock worth $94,929,000 after purchasing an additional 88,119 shares during the last quarter. Bridger Management LLC grew its position in Alnylam Pharmaceuticals by 30.3% during the 4th quarter. Bridger Management LLC now owns 500,219 shares of the biopharmaceutical company’s stock worth $63,553,000 after purchasing an additional 116,286 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 15.5% in the fourth quarter. Bank of New York Mellon Corp now owns 395,267 shares of the biopharmaceutical company’s stock valued at $50,219,000 after acquiring an additional 53,162 shares in the last quarter. 90.56% of the stock is currently owned by institutional investors.
Several brokerages have recently weighed in on ALNY. Credit Suisse Group set a $151.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. B. Riley lowered their target price on shares of Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating on the stock in a report on Friday, February 16th. BMO Capital Markets lowered their target price on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 2nd. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $137.05.
ALNY stock opened at $99.47 on Friday. The stock has a market cap of $10.06 billion, a P/E ratio of -18.35 and a beta of 2.73. Alnylam Pharmaceuticals, Inc. has a 52 week low of $62.96 and a 52 week high of $153.99. The company has a current ratio of 14.61, a quick ratio of 14.61 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The firm had revenue of $21.90 million for the quarter, compared to the consensus estimate of $35.23 million. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.25) earnings per share. equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.